CNBC January 20, 2026
Key Points
– Drug pricing, looming patent cliffs, dealmaking and the first year of the second Trump administration dominated conversations at the annual JPMorgan Healthcare Conference in San Francisco.
– Top executives from drugmakers of all sizes met with investors to map out their plans for 2026 and beyond.
– Big pharma is grappling with the impact of new drug pricing deals with President Donald Trump and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.
Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0.
Those are among the themes that dominated conversations last week as drugmakers of all sizes met with investors to map out their plans for 2026 and beyond...
Today's Sponsors
Today's Sponsor